• Send Us A Tip
  • Calling all Tech Writers
  • Advertise
Wednesday, July 9, 2025
  • Login
TechStory
  • News
  • Crypto
  • Gadgets
  • Memes
  • Gaming
  • Cars
  • AI
  • Startups
  • Markets
  • How to
No Result
View All Result
  • News
  • Crypto
  • Gadgets
  • Memes
  • Gaming
  • Cars
  • AI
  • Startups
  • Markets
  • How to
No Result
View All Result
TechStory
No Result
View All Result
Home Capsule

Gates Foundation commits up to $120M to support access to new COVID-19 pill

by Aashish Sehrawat
October 21, 2021
in Capsule, News, Women, World
Reading Time: 2 mins read
0
Capsules of Merck’s new investigational COVID-19 drug molnupiravir.

Image Credit: Merck

TwitterWhatsappLinkedin
Capsules of Merck’s new investigational COVID-19 drug molnupiravir.
Image Credit: Merck

The Bill and Melinda Gates Foundation announced Tuesday that it will contribute up to $120 million to help low-income countries have access to a new COVID-19 treatment tablet.

You might also like

New Academic Studies Allege Uber’s Opaque Algorithm Systematically Boosts Profits at Expense of Drivers and Passengers

CoreWeave’s Game-Changing $9 Billion Acquisition of Core Scientific

Capgemini Announces its Intention to Acquire WNS (Holdings) Limited

According to preliminary clinical trial data revealed by pharma giant Merck earlier this month, molnupiravir reduces the likelihood of hospitalization or mortality in newly diagnosed patients by nearly half. The pill was developed in collaboration with Ridgeback Biotherapeutics and evaluated in high-risk individuals.

Merck is requesting an emergency use licence for the tablet from the US Food and Drug Administration, and regulatory bodies in other countries will weigh in as well. The pill has been generally hailed as the first oral, simple-to-use prospective COVID-19 treatment.

The Gates Foundation’s new investment will go toward the development and production of generic versions of molnupiravir. For example, the foundation has given $2.4 million in grants to enterprises to help them get ready to produce and $1.3 million to help them build low-cost manufacturing techniques.

In a statement, Melinda French Gates, co-chair of the foundation, said, “Today’s commitment will ensure that more people in more countries get access to the promising drug molnupiravir.” She also urged other donors, such as foundations and governments, to take action.

The Gates Foundation’s entire funding commitment for pandemic-related initiatives now stands at $1.9 billion as a result of this new initiative. COVID-19 diagnostics, treatments, and vaccinations were developed, manufactured, and delivered with the help of the foundation.

To end this pandemic, we must ensure that everyone has access to life-saving treatments, no matter where they live.

This commitment will help expand access to the promising drug molnupiravir, but it’s not the end of the story. We need other donors to act.https://t.co/9LdGDp5Dhs

— Melinda French Gates (@melindagates) October 20, 2021

Molnupiravir distribution and access are top of mind for government leaders.

In June, the US government agreed to pay Merck $1.2 billion for 1.7 million pills, which works out to $712 for a five-day treatment cycle. Other countries are putting orders for the medicine as well.

Merck had reached licencing deals with eight major generic manufacturers by early October. According to The New York Times, India’s generic makers will sell the pills at a lesser price in impoverished countries, although many countries with low immunisation rates are not part of such arrangements.

Efforts to ensure that low-income nations have access to molnupiravir are being made against a backdrop of delayed vaccine distribution.

According to STAT News, 98 percent of individuals in low-income nations have not been vaccinated, and the international organisation in charge of the effort, COVAX, has only dispatched 330 million of the 2 billion doses anticipated.

The World Health Organization and two Gates Foundation-funded organisations, Gavi, the Vaccine Alliance, and the Coalition for Epidemic Preparedness Innovations, are leading COVAX.

Bill Gates recently stated in an editorial that manufacturing barriers, not intellectual property limitations, have been the most significant impediment to immunisation.

“The world learned the hard way with COVID-19 vaccines that unless we are willing to invest at-risk and at-scale as soon as promising technologies emerge – and ideally before – then there will be limited access for some time, even when need and demand are clear,” said a Gates Foundation spokesperson in an email, referring to the risk of investing in a product before regulatory approval. “We are aiming to do our part to ensure resources are not a barrier to equitable access to molnupiravir.”

An FDA panel will meet Nov. 30 to discuss the safety and effectiveness of the new pill, with a decision on emergency use expected soon after.

Tags: billgatesmelindagatesMicrosoft
Tweet54SendShare15
Previous Post

Tesla 4680 battery cells production line showing positive results

Next Post

Museums join OnlyFans to keep ‘explicit’ art from social media censors

Aashish Sehrawat

Recommended For You

New Academic Studies Allege Uber’s Opaque Algorithm Systematically Boosts Profits at Expense of Drivers and Passengers

by Anochie Esther
July 9, 2025
0
Uber

Uber, the global ride-hailing giant, is once again facing intense scrutiny over its pricing practices. Two independent academic studies, one from the prestigious Columbia Business School in the...

Read more

CoreWeave’s Game-Changing $9 Billion Acquisition of Core Scientific

by Anochie Esther
July 9, 2025
0
CoreWeave

In a landmark deal signaling a significant shift in the competitive landscape of AI infrastructure, CoreWeave, a leading AI hyperscaler, has announced its intent to acquire Core Scientific,...

Read more

Capgemini Announces its Intention to Acquire WNS (Holdings) Limited

by Anochie Esther
July 9, 2025
0
Capgemini

In a significant move set to reshape the digital services sector, global IT giant Capgemini has announced its intention to acquire WNS (Holdings) Limited, a leading digital-led business...

Read more
Next Post
Museums join OnlyFans to keep ‘explicit’ art from social media censors

Museums join OnlyFans to keep ‘explicit’ art from social media censors

Please login to join discussion

Techstory

Tech and Business News from around the world. Follow along for latest in the world of Tech, AI, Crypto, EVs, Business Personalities and more.
reach us at [email protected]

Advertise With Us

Reach out at - [email protected]

BROWSE BY TAG

#Crypto #howto 2024 acquisition AI amazon Apple bitcoin Business China cryptocurrency e-commerce electric vehicles Elon Musk Ethereum facebook flipkart funding Gaming Google India Instagram Investment ios iPhone IPO Market Markets Meta Microsoft News NFT samsung Social Media SpaceX startup startups tech technology Tesla TikTok trend trending twitter US

© 2024 Techstory.in

No Result
View All Result
  • News
  • Crypto
  • Gadgets
  • Memes
  • Gaming
  • Cars
  • AI
  • Startups
  • Markets
  • How to

© 2024 Techstory.in

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?